UDP-glucuronic acid is used by many pathogenic bacteria in the construction of an antiphagocytic capsule that is required for virulence. The enzyme UDP-glucose dehydrogenase catalyzes the NAD ؉ -dependent 2-fold oxidation of UDP-glucose and provides a source of the acid. In the present study the recombinant dehydrogenase from group A streptococci has been purified and found to be active as a monomer. The enzyme contains no chromophoric cofactors, and its activity is unaffected by the presence of EDTA or carbonyl-trapping reagents. Initial velocity and product inhibition kinetic patterns are consistent with a bi-uni-uni-bi ping-pong mechanism in which UDP-glucose is bound first and UDPglucuronate is released last. UDP-xylose was found to be a competitive inhibitor (K i , 2.7 M) of the enzyme. The enzyme is irreversibly inactivated by uridine 5 -diphosphate-chloroacetol due to the alkylation of an active site cysteine thiol. The apparent second order rate constant for the inhibition (k i /K i ) was found to be 2 ؋ 10 3 mM ؊1 min ؊1 . Incubation with the truncated compound, chloroacetol phosphate, resulted in no detectable inactivation when tested under comparable conditions. This supports the notion that uridine 5 -diphosphate-chloroacetol is bound in the place of UDP-glucose and is not simply acting as a nonspecific alkylating agent.The enzyme UDP-glucose dehydrogenase (UDPGDH) 1 catalyzes the NAD ϩ -dependent oxidation of UDP-glucose to UDPglucuronic acid (Fig. 1). It belongs to a small group of dehydrogenases that are able to carry out the 2-fold oxidation of an alcohol to an acid without the release of an aldehyde intermediate (1). Much of the work to date has focused on the properties and mechanism of the beef liver enzyme, and relatively little is known about the enzyme purified from bacterial sources (2-4). In many strains of bacteria that act as human pathogens, UDPGDH provides the UDP-glucuronic acid required for the construction of an antiphagocytic capsular polysaccharide. It is well established that the formation of the capsule is required for virulence (5, 6), and it is thought that the capsule enables the bacteria to evade the host's immune system (7,8). Group A and C streptococci are mammalian pathogens that use UDPGDH in the synthesis of a capsule composed of hyaluronic acid (a polysaccharide consisting of alternating glucuronic acid and N-acetylglucosamine residues) (9, 10). Many of the known strains of Streptococcus pneumoniae also use UDP-glucuronic acid in the construction of their polysaccharide capsule (11), and it has recently been shown that UDPGDH is required for capsule production in S. pneumoniae type 3 (12). The encapsulated Escherichia coli K5 is also known to use the enzyme for a similar purpose (2, 13). The hasB gene that encodes for UDPGDH in group A streptococci (Streptococcus pyogenes) has been cloned and overexpressed in Escherichia coli (14). Its gene product shares 57% sequence identity and 74% sequence similarity with the S. pneumoniae enzyme (15, 16). These properties make th...